TTField
Showing 1 - 8 of 8
NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy
Recruiting
- Glioblastoma
- Tumor samples from patients treated with TTFields at initial diagnosis.
- Tumor samples from patients treated with TTFields at tumor recurrence.
-
Milwaukee, WisconsinFroedtert & the Medical College of Wisconsin
Feb 9, 2022
Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
- concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
-
Jerusalem, IsraelShaare Zedek Medical Center
Jan 22, 2023
1-5 Brain Metastases From NSCLC Trial in Worldwide (NovoTTF-100A device, Best Standard of Care)
Unknown status
- 1-5 Brain Metastases From Non-Small Cell Lung Cancer
- NovoTTF-100A device
- Best Standard of Care
-
Prague, Czech Republic
- +6 more
Sep 20, 2016
Pancreatic Adenocarcinoma Trial in Spain, Switzerland (NovoTTF-100L, Gemcitabine, nab-Paclitaxel)
Unknown status
- Pancreatic Adenocarcinoma
- NovoTTF-100L
- +2 more
-
Elche, Spain
- +5 more
Sep 12, 2017
Glioblastoma Multiforme Trial in Worldwide (NovoTTF-100A device, Temozolomide)
Completed
- Glioblastoma Multiforme
- NovoTTF-100A device
- Temozolomide
-
Birmingham, Alabama
- +88 more
Apr 7, 2017
Recurrent Glioblastoma Multiforme Trial in United States (NovoTTF-100A)
Terminated
- Recurrent Glioblastoma Multiforme
- NovoTTF-100A
-
Birmingham, Alabama
- +11 more
Feb 29, 2016